Pasithea therapeutics announces opening of enrollment in the u.s. for its phase 1 trial of pas-004

-- activation of four u.s. sites for phase 1 clinical trial of pas-004 to evaluate safety, dose, key biomarker data and preliminary efficacy -- -- plans to open three additional sites in eastern europe in the coming months -- -- preliminary interim data expected in 2h 2024 -- south san francisco, calif. and miami, feb. 13, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced the activation of four clinical trial sites in the united states.
KTTA Ratings Summary
KTTA Quant Ranking